Lumexa Imaging hauled in $462.5 million during its initial public offering, far exceeding the $200 million the outpatient ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

CMS spending on skin substitutes is rising. New policies are an important first step in reform to ensure patient access and ...

Unmatched expertise in patient recruitment and retentionOne of the critical challenges in clinical trials is patient ...

Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...

Lumos Labs has obtained a clearance from the FDA for its popular Lumosity brain training platform, greenlighting a version of ...

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...

The FDA’s oversight of medical device recalls continues to be plagued by staffing challenges—forcing some activities to be ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

OTR Therapeutics may still be keeping its own pipeline under wraps, but Zealand Pharma has seen enough promise in the Chinese ...